Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to
grow and spread more slowly.
PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients
with newly diagnosed ACTH-secreting pituitary tumor (Cushing disease).
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)